SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma

BACKGROUND: Papillary renal cell carcinoma (PRCC) is the most common subtype of non-clear cell renal cell carcinoma (RCC) and accounts for 10–15% of RCCs. Many PRCC cases are MET-driven, characterized by genomic abnormalities resulting in dysregulation of the MET signaling pathway, making these abno...

Descripción completa

Detalles Bibliográficos
Autor principal: Chouieri, Toni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Trials in Progress Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445576/
http://dx.doi.org/10.1093/oncolo/oyad216.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445576/
http://dx.doi.org/10.1093/oncolo/oyad216.018

Ejemplares similares